Role of CYP2C19 Polymorphism in the Drug Interaction Between Clopidogrel and Omeprazole
Status:
Completed
Trial end date:
2014-06-30
Target enrollment:
Participant gender:
Summary
Clopidogrel, an inhibitor of ADP induced platelet aggregation and activation, is one of the
most commonly used drugs in patients with cardiovascular disease. The specific aim of the
proposed study is to determine whether the interaction between proton-pump inhibitors (PPIs)
and clopidogrel is dependent on CYP2C19 haplotype.